姓    名：王伽伯                                        

专业方向：中药药理学

办公电话：无

电子邮件：jiabo_wang@ccmu.edu.cn

通讯地址：云南省大理州大理市下关镇万花路22号大理大学下关校区

简历：

教授，博士生导师，北京学者、国家级科技领军人才、北京市杰出青年科学基金获得者、青年岐黄学者。国家中医药管理局高水中重点学科（中药药理学）学科带头人，国家中医药传承创新团队（中医药间接作用）团队带头人，北京市重点实验室（中医药间接作用原创药研发）主任。中华中医药学会中成药分会主委、中国毒理学会临床毒理专委会主委等。主要从事中药药理学、临床中药学与创新药研究，功能代谢组学等。主持国家自然科学基金重点项目、国家科技支撑计划课题等12项，在Journal of Advanced Research、Acta Pharmaceutica Sinica B、Hepatology、Trends in Food Science & Technology等发表论文200余篇。入选爱思唯尔中国高被引学者、全球前2%顶尖科学家终身影响力榜单。获中国药学发展奖“突出成就奖”。培养博士和硕士研究生20余人。

研究领域：中药药理学、临床中药学与创新药研究

代表论著（限10篇）：

1. Dan Gao, Wei-wei Yi, Bo Liu, Cong-en Zhang, Cui-cui Yang, Li Zeng, Lin Li, Guangbin Luo*, Lan Zhang*, Zhen-yu Ju*,Jia-bo Wang*. Tetrahydroxy stilbene glucoside rejuvenates aging hematopoietic stem cells with predilection for lymphoid differentiation via AMPK and Tet2. Journal of Advanced Research, 2025;70: 515–529 
2. Ye Luo#, Xu Zhao#, Ruilin Wang#, Xiaoyan Zhan, Tianyi Zhang, Tingting He, Jing Jing, Jianyu Li, Fengyi Li, Ping Zhang, Junling Cao, Jinfa Tang, Zhijie Ma, Tingming Shen, Shuanglin Qin, Ming Yang, Jun Zhao, Zhaofang Bai*, Jiabo Wang*, Aiguo Dai*, Xiangmei Chen*, Xiaohe Xiao*. Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (iEC-Eff): A demonstration study. Acta Pharmaceutica Sinica B,2025;15(2):909-918.
3. Qing Pu, Han Gao, Dake Xiao, Manyuan Wang, Zhiyun Yang, Qiang He, Min Liu, Xuejin Zhu, Tao Pan, Zhitao Ma*, Jiabo Wang*, Yao Liu*. Tetramethylpyrazine: A fermented alcohol product that mitigates alcoholic liver disease in mice. Free Radical Biology and Medicine, 2025; 16;236:160-175.
4. Wenjuan Wu, Ying Li, Pengyue Song, Qingbin Xu, Nan Long, Peng Li, Lidong Zhou, Bin Fu, Jiabo Wang*, Weijun Kong*. Metal-organic framework (MOF)-based sensors for exogenous contaminants in food: Mechanisms, advances, and prospects. Trends in Food Science & Technology, 2023; 138: 238–271
5. Jiabo Wang#, Haibo Song#, Feilin Ge#, Peng Xiong, Jing Jing, Tingting He, Yuming Guo, Zhuo Shi, Chao Zhou, Zixin Han, Yanzhong Han, Ming Niu, Zhaofang Bai, Guangbin Luo, Chuanyong Shen*, Xiaohe Xiao*.Landscape of DILI-related adverse drug reaction in China Mainland. Acta Pharmaceutica Sinica B, 2022;12(12):4424-4431
6. Yuan Gao, Jia-bo Wang*. Invited Commentary: Indirect action pattern: A remote and cross-organ pharmacological mechanism for drug innovation. Acta Pharmaceutica Sinica B, 2022; 12(8): 3448-3450
7. Jia- Bo Wang#, Ang Huang#, Yijin Wang#, Dong Ji#, Qing- Sheng Liang, Jun Zhao, Guangde Zhou, Shuhong Liu, Ming Niu, Ying Sun, Hui Tian, Guang-Ju Teng, Bin- Xia Chang, Jing- Feng Bi, Xiao- Xia Peng, Shaojie Xin, Huan Xie, Xiong Ma, Yi-Min Mao, Suthat Liangpunsakul, Romil Saxena, Guruprasad P. Aithal*, Xiao-He Xiao*, Jingmin Zhao*, Zhengsheng Zou*. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial. Alimentary Pharmacology & Therapeutics, 2022;55(10): 1297- 1310
8. Zhang Le; Niu Ming; Wei Ai-wu; Tang Jin-fa; Tu Can; Bai Zhao-fang; Zou Zhengsheng; Xiao Xiao-he*; Liu You-ping*; Wang Jiabo*. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum.Archives of Toxicology, 2020, 94(1): 245-256
9. Jia Tong; Jingjing Gao; Qingzhen Liu; Chenyang He; Xing Zhao; Yawei Qi; Tiangang Yuan; Pengyan Li; Ming Niu; Dongyao Wang; Le Zhang; Weiyong Li; Jiabo Wang*; Zhongjian Zhang*; Shiyong Peng*. Resveratrol derivative excited postsynaptic potentiation specifically via PKCβ-NMDA receptor mediation. Pharmacological Research, 2020, 152: 104618
10. Chaopeng Li#; Tai Rao#; Xiaoping Chen; Zhengsheng Zou; Aiwu Wei; Jinfa Tang; Peng Xiong; Pengyan Li; Jing Jing; Tingting He; Zhaofang Bai; Jiye Yin; Zhirong Tan; Peng Yu; Honghao Zhou; Jiabo Wang*; Xiaohe Xiao*; Dongsheng Ouyang*. HLA-B*35:01Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans. Hepatology, 2019, 70(1): 346-357

承担科研项目情况（限5项）：

1. 北京学者计划培养项目，项目编号：2025119，名称：中医药间接作用理论及应用，01-2031.12，在研，主持
2. 国家中医药传承创新团队，项目编号：ZYYCXTD-C-202402，名称：中医药间接作用研究与转化应用，09-2026.08，在研，主持
3. 国家中医药管理局高水平中医药重点学科建设项目，编号：ZYYZDXK-2023004，名称：中药药理学，29-2026.12，在研，主持
4. 国家自然科学基金联合基金重点项目，编号：U21A20412，名称：基于通腑泄热的大黄治疗重症酒精性肝炎的物质基础和作用机制研究，01-2025.12，结题，主持